MAIA activates new site for THIO-101 Phase II trial
MAIA activates new site for THIO-101 Phase II trial
MAIA Biotechnology has activated new US site, the Winship Cancer Institute of Emory University, and opened patient enrolment for the Phase II THIO-101 expansion trial evaluating its telomere-targeting agent, ateganosine, as a third-line therapy for NSCLC.
